Jennifer Munkley

The paper profiles Siglec-7 and Siglec-9 ligands across LuCaP PDX models and clinical specimens, showing lineage-independent glyco-immune checkpoint expression and model-dependent glycan remodelling under castration.

Siglec-15 is found on prostate tumour cells, macrophages and osteoclasts; antibody blockade reduced macrophage immunosuppression, osteoclast formation and tumour growth in mice (CD8+ T-cell-dependent).

This study shows sTn is upregulated in prostate cancer and correlates with poor patient survival, suggesting it as a prognostic biomarker and therapeutic target.

This study identifies Siglec-engaging sialoglycans as upregulated in prostate cancer and shows they can be targeted to suppress bone metastasis using a bisialidase.

This study shows RBMX and RBMXL2 proteins regulate splicing of ultra-long exons by repressing cryptic splice sites, with RBMXL2 rescuing splicing defects in somatic cells.

The paper shows RBMX prevents non-productive splicing of ultra-long exons, maintaining genome stability by blocking aberrant splice sites in genes like ETAA1.

The paper shows androgen-regulated ESRP2 transcription controls alternative splicing in prostate cancer, with implications for metastasis.